Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis - Wikidata - awgldk - TriplyDB

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis

http://www.wikidata.org/entity/Q28239197

about

Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis Cytokines and cytokine profiles in human autoimmune diseases and animal models of autoimmunity TRAF1-C5 as a risk locus for rheumatoid arthritis--a genomewide study Adalimumab (a fully human anti-tumour necrosis factor alpha monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials Physiology and immunology of the cholinergic antiinflammatory pathway Where is biological therapy going?Phenotypic characteristics of human monocytes undergoing transendothelial migration Endothelial cell phenotypes in the rheumatoid synovium: activated, angiogenic, apoptotic and leaky Interferon-beta for treatment of rheumatoid arthritis?Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study Circulating tumour necrosis factor-alpha bioactivity in rheumatoid arthritis patients treated with infliximab: link to clinical response JNK1 is not essential for TNF-mediated joint disease.The role and clinical implications of G6PI in experimental models of rheumatoid arthritis CD44 in rheumatoid arthritis Serum cartilage oligomeric matrix protein (COMP) decreases in rheumatoid arthritis patients treated with infliximab or etanercept Current perspectives on synovitis.The stressed synovium Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-alpha therapy and other novel approaches The contact-mediated response of peripheral-blood monocytes to preactivated T cells is suppressed by serum factors in rheumatoid arthritis.Biologic interventions for fatigue in rheumatoid arthritis Scanning for Therapeutic Targets within the Cytokine Network of Idiopathic Inflammatory Myopathies A Neurologist's Guide to TNF Biology and to the Principles behind the Therapeutic Removal of Excess TNF in Disease Review article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel disease Lymphotoxin and TNF: how it all began-a tribute to the travelers Anti-TNF therapy: past, present and future Excess cerebral TNF causing glutamate excitotoxicity rationalizes treatment of neurodegenerative diseases and neurogenic pain by anti-TNF agents Inflammation induced loss of skeletal muscle Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn's disease Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases Identification and characterization of a pro-tumor necrosis factor-alpha-processing enzyme from the ADAM family of zinc metalloproteases CDP-870 (certolizumab) in rheumatoid arthritis Induction of the cytokine signal regulator SOCS3/CIS3 as a therapeutic strategy for treating inflammatory arthritis Infliximab.Molecular interactions between T cells and fibroblast-like synoviocytes: role of membrane tumor necrosis factor-alpha on cytokine-activated T cells.Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides.Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-alpha responses What is the utility of routine ANA testing in predicting development of biological DMARD-induced lupus and vasculitis in patients with rheumatoid arthritis? Data from a single-centre cohort.Efficient generation of respiratory syncytial virus (RSV)-neutralizing human MoAbs via human peripheral blood lymphocyte (hu-PBL)-SCID mice and scFv phage display libraries.A novel method predicting clinical response using only background clinical data in RA patients before treatment with infliximab.

P2860

Q21134808-DBADB6B3-1547-45EF-9590-428FF6348E87 Q22306446-6BC59FA4-884B-48C6-95AD-3BBDE4EA209D Q24657292-C6773E73-75FC-46CE-A8AE-6EF5BEE2FA9A Q24675105-F447A6C3-05DE-4CFB-90AD-F82358E3EA8F Q24681833-CB36D203-FA63-4D34-B136-045826F489EC Q24792345-EB11304F-5F20-4923-B19F-867018B6DD4D Q24793076-60943C7A-02BA-48BE-8602-B5697B0688E2 Q24793680-8F2B1CF8-0CB8-4606-8C66-35EFCC0C4E3D Q24793971-7A5F66F3-6C55-4A74-AC2D-EB29C55DCE65 Q24798468-571EF508-556C-4F08-965C-10F279C85B5A Q24799187-3D0A4E0C-756C-4897-8029-C4BB08140E24 Q24799357-757DCA71-291E-4035-9208-3441D43F3A53 Q24799403-759BECEF-CE04-4771-AB1D-18D84B5A089B Q24804352-425D5132-EB4A-4B7B-AEFC-3CE4C35CA262 Q24804764-1F43B2FA-C93A-413F-A210-6AC3B6757B76 Q24804893-CF2AE632-82E3-4E3C-9954-F3C095DA17E7 Q24805297-B9F2C908-ABAD-4247-A152-67EF33CE4E6E Q24806367-763D48B5-EBDE-4978-9C84-475B254FAAE7 Q24812699-19FE7CF5-90FA-422A-83E8-694E26809343 Q26471538-02EE80F9-1E6D-4F57-9F94-678AB4109EC8 Q26798209-8F03972D-3986-4EA4-B6EE-F01FA011B186 Q26801912-9F640001-9A1C-4A48-9503-7BD353ED17A8 Q26822029-00D6CFBF-3A71-4689-BD1C-4B3565EE8FBB Q26865649-64D5D145-5CE5-4F70-B6E9-F9D708050EAE Q26997311-57249347-67BE-4788-8D15-3467ADF614A3 Q28075692-5D6C9ED0-E6B2-4228-B251-AA05DDF0A1B0 Q28083759-31613EB6-5AD3-426A-8F5F-0AAB9CDA45F1 Q28143405-BEDF6E2C-66D0-4CEF-8049-16A69C60CC54 Q28144207-CE2B8238-6BE4-478F-8620-EC7288D9B127 Q28206018-1D6BDD98-12F8-4EC5-B62E-781F120E5220 Q28249632-E7F3690A-D20F-4D8E-9BEF-193E0B3942F7 Q28254498-7CC28624-68AD-4057-A80B-692FD3530D07 Q28366650-D17DF67A-6611-4D8F-ABD6-6F3673E97188 Q30307998-A886D40C-3489-4EA5-92F0-1DE251189E7F Q30480303-10EC2EB5-720E-4AF7-B6FD-5A7ADCC40BBC Q30667754-C2D51829-A018-427A-B7E8-A0D57C0F4947 Q30732295-FD1E6233-87B3-448E-9277-C8BFA2331D2F Q30826279-9B2DA90E-2D54-4ECB-83EE-EEBD8446AC83 Q30933288-3D700FD6-ABA0-4BFB-8EE8-196609F40E0B Q31090628-6C144802-C21E-4319-AF83-17BF472CFFED

P2860

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis

http://www.wikidata.org/entity/Q28239197

description

1994 nî lūn-bûn

@nan

1994 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

1994 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

1994年の論文

@ja

1994年論文

@yue

1994年論文

@zh-hant

1994年論文

@zh-hk

1994年論文

@zh-mo

1994年論文

@zh-tw

1994年论文

@wuu

name

Randomised double-blind compar ...... lacebo in rheumatoid arthritis

@ast

Randomised double-blind compar ...... lacebo in rheumatoid arthritis

@en

Randomised double-blind compar ...... lacebo in rheumatoid arthritis

@nl

type

label

Randomised double-blind compar ...... lacebo in rheumatoid arthritis

@ast

Randomised double-blind compar ...... lacebo in rheumatoid arthritis

@en

Randomised double-blind compar ...... lacebo in rheumatoid arthritis

@nl

prefLabel

Randomised double-blind compar ...... lacebo in rheumatoid arthritis

@ast

Randomised double-blind compar ...... lacebo in rheumatoid arthritis

@en

Randomised double-blind compar ...... lacebo in rheumatoid arthritis

@nl

P1433

Q28239197-00918B73-0D44-41C2-A66A-1FDEB2875AE4

P1476

Q28239197-753F03A4-3D5D-4081-8EC2-0E0440FF4783

P2093

Q28239197-0D7C26E4-D28A-4E22-9E60-E53EF042A253

Q28239197-55612050-A70F-4C7D-8638-24CC88B6EBA6

Q28239197-79277C98-8920-4ED9-8927-42571DA65873

Q28239197-7DA4C28C-3FD8-48A8-A93E-7A0CEAEC6F0A

Q28239197-8D8F3FE0-3F1D-44D2-AEB5-3312A0A2AD50

Q28239197-95A74EAD-0355-4B60-B914-D4E9DF260748

Q28239197-9F96136E-F4F4-4B2E-9E6B-CB4530CF6D39

Q28239197-B1890728-DEA4-446B-BA6C-454F65DAEF46

Q28239197-D74ADFE6-6BED-4113-A0AB-801367AEFE92

Q28239197-F8A37EF9-A4AC-4A69-924D-8186A179C2F1

P304

Q28239197-33378138-0766-4F7A-83A7-369EB2523580

P31

Q28239197-AEB0933B-79DE-43B3-A251-E8F3DAA9D282

P3181

Q28239197-78F43C0F-19DE-4835-AA6C-23D194CBB54C

P356

Q28239197-CF8A0C69-458C-475A-A763-75B71237A123

P407

Q28239197-ECBDBB0C-830C-411E-A31F-628F66B615CC

P433

Q28239197-BBB6F1B1-1896-4CD5-A23A-5CD9B1207043

P478

Q28239197-BDDFA4E5-34D9-48B8-9968-892B85D2ECCF

P577

Q28239197-540FFA5B-6E58-4262-8503-65E444313751

P698

Q28239197-C48A49CF-4E94-4049-8CD9-8F1DFD0D38A8

P921

Q28239197-3677999F-AE31-4C9B-914D-9A3C259223CA

Q28239197-6912BD15-2B3E-4F3E-A0D3-F40BD09532A3

Q28239197-d3baaa30-6839-42fb-b46b-ab9257c91700

P3181

P356

S0140-6736(94)90628-9

P1433

P1476

Randomised double-blind compar ...... lacebo in rheumatoid arthritis

@en

P2093

B Leeb

http://www.w3.org/2001/XMLSchema#string

C Antoni

http://www.w3.org/2001/XMLSchema#string

F C Breedveld

http://www.w3.org/2001/XMLSchema#string

H Bijl

http://www.w3.org/2001/XMLSchema#string

J D Macfarlane

http://www.w3.org/2001/XMLSchema#string

J R Kalden

http://www.w3.org/2001/XMLSchema#string

J S Smolen

http://www.w3.org/2001/XMLSchema#string

M Feldmann

http://www.w3.org/2001/XMLSchema#string

M J Elliott

http://www.w3.org/2001/XMLSchema#string

R N Maini

http://www.w3.org/2001/XMLSchema#string

P304

1105-10

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3625974

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/S0140-6736(94)90628-9

http://www.w3.org/2001/XMLSchema#string

P407

P433

8930

http://www.w3.org/2001/XMLSchema#string

P478

344

http://www.w3.org/2001/XMLSchema#string

P577

1994-10-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

7934491

http://www.w3.org/2001/XMLSchema#string

P921